CG Oncology says Phase 3 BOND-003 data for cretostimogene in BCG-unresponsive bladder cancer publish in Lancet Oncology

PUBT · 2d ago
CG Oncology says Phase 3 BOND-003 data for cretostimogene in BCG-unresponsive bladder cancer publish in Lancet Oncology
  • CG Oncology reported publication of pivotal Phase 3 BOND-003 Cohort C results in The Lancet Oncology; results were already presented via the journal release.
  • The study showed cretostimogene delivered durable complete responses in high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
  • Bladder preservation remained high through two years, supporting a bladder-sparing alternative to cystectomy for many patients.
  • Safety profile was favorable, with no severe treatment-related events reported and rapid resolution of side effects.
  • Data support a potential regulatory path for cretostimogene, positioning it as a possible foundational monotherapy in NMIBC.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607271845PRIMZONEFULLFEED9798953) on July 27, 2026, and is solely responsible for the information contained therein.